RAReza Alaghehbandan

Reza Alaghehbandan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Reza Alaghehbandan has a total of 446 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Concurrent Adenoid Cystic/Basal Cell Carcinoma and Acinar Adenocarcinoma of the Prostate: Comprehensive Molecular Analysis of Both Tumor Component

    by Kristyna Pivovarcikova, Reza Alaghehbandan, Martina Bradova, Nikola Ptakova, Petr Martinek, Tomas Vanecek, Michal Michal, Ondrej Fiala, Milan Hora, Ondrej Ondic

    Adenoid cystic/basal cell carcinoma (ACBCC) of the prostate is a rare tumor, with only about 100 tumors reported in the literature. We present a 66-year-old man with incidental finding of prostatic cancer duplicity—ACBCC of the prostate and prostatic acinar adenocarcinoma in radical prostatectomy specimen. Prostatic acinar adenocarcinoma was of Gleason score 6 (3 + 3), focally present at surgical margin, exhibited perineural invasion but no extraprostatic extension. Concurrently, ACBCC was detected, the tumor exhibited adenoid cystic-like morphology, with multifocal involvement of the resection margins and extraprostatic extension. This coincidence presented a unique opportunity to comprehensively examine the molecular characteristics of both tumors. SETD2 mutation was identified in ACBCC, while it was absent in acinar adenocarcinoma. No significant differences were detected by other genetic analyses, and both tumors clustered together within “Prostatic adenocarcinoma” control group and separated from adenoid cystic carcinoma of other locations using methylation profiling.

  • Open Access

    Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression

    by Jane K Nguyen, Marcello P Toscano, Jianbo Li, Sean R Williamson, Christopher G Przybycin, Chia‐Sui Kao, Jonathan L Myles, Kristýna Pivovarčíková, Marián Švajdler, Marek Brousil, et al.

    Objective: Histological grading is a key predictor of progression in non‐muscle‐invasive bladder cancer (NMIBC). The WHO 1973 three‐tier system is limited by heterogeneity within the G2 category, whereas the WHO 2004/2016 binary classification reduces prognostic resolution by grouping biologically diverse tumours into broad low‐grade (LG) and high‐grade (HG) categories. We aimed to evaluate the prognostic performance of hybrid grading systems compared with WHO 2004/2016, while further characterizing the histomorphological continuum of non‐invasive papillary urothelial carcinoma. Methods: Non‐invasive papillary urothelial carcinomas (2012–2023; n = 472) were reviewed and reclassified by two urological pathologists according to WHO 2004/2016, hybrid three‐tier and four‐tier systems, and an investigational five‐tier framework (Grades I, IIA, IIB, IIIA, IIIB) integrating architectural, cytological and proliferative features. Primary endpoints were recurrence, grade progression and T1+ stage progression, assessed using ROC analysis, Cox proportional hazards regression and model‐performance metrics (AIC, BIC, C‐index). Results: Increasing morphological atypia was associated with larger tumour size, greater multifocality and progressively higher progression risk, with events concentrated in Grades IIIA and IIIB. All systems showed limited recurrence discrimination (C‐index 0.54–0.56). For T1+ progression, discrimination improved with increasing stratification (AUC 0.754 for WHO 2004/2016 vs. 0.815, 0.828 and 0.827 for the hybrid three‐tier, four‐tier and five‐tier systems, respectively; all P < 0.001). The Hybrid 3‐Tier model achieved the most favourable AIC and BIC, while the five‐tier model yielded the highest C‐index (0.818). Conclusions: Hybrid grading systems improve progression‐risk stratification in non‐invasive papillary urothelial carcinoma compared with WHO 2004/2016, with most benefit achieved by the Hybrid 3‐Tier framework. These findings support the concept of a histomorphological continuum of progression risk and favour continued refinement of biologically informed hybrid grading for NMIBC risk stratification.


  • Open Access

    GPNMB Expression in Clear Cell Papillary Renal Cell Tumour: Limited Specificity and a Potential Diagnostic Pitfall in Clear Cell Renal Neoplasms

    by Josef Skopal, Reza Alaghehbandan, Maryna Slisarenko, Tomas Vanecek, Veronika Hajkova, Joanna Rogala, Monica Ulamec, Levente Kuthi, Michal Pavlovsky, Richard Dolezilek, et al.

    GPNMB is considered a relatively specific marker for MiTF-associated renal cell carcinoma (RCC) and renal neoplasms with mTOR pathway alteration. However, more recent studies have broadened this view, demonstrating that its specificity is lower than previously thought due to expression in other renal tumour subtypes. In this study, we evaluated GPNMB expression in a cohort of clear cell papillary renal cell tumours (CCPRCT) and compared to a cohort of renal epithelial neoplasms with clear cell morphology.A total of 35 CCPRCTs were analysed, along with a control cohort of 50 renal tumours, comprising clear cell RCC (CCRCC; n=32), multilocular cystic renal neoplasm of low malignant potential (MCNLMP; n=6), and RCC with fibromyomatous stroma (RCC FMS; n=12). All CCPRCTs had typical morphologic features with strong and diffuse CK7 positivity. The majority of CCPRCT (89%) showed GPNMB reactivity (diffuse weak/moderate in 20, and focal weak/moderate in 11 tumours). In the control group, 92% (35/38) did not show any GPNMB expression, including 29 CCRCCs and 6 MCNLMPs. Among 12 RCC FMS, three tumours harbouring TSC1/2 alterations demonstrated diffuse strong GPNMB staining. In contrast, among 9 MTOR-mutated RCC FMS, diffuse moderate staining was observed in only 2 tumours; 6 tumours exhibited focal weak to moderate reactivity, and one showed diffuse weak staining.Weak to moderate GPNMB expression is frequently observed in CCPRCT. The GPNMB staining pattern identified in a substantial proportion of MTOR‑mutated RCC FMS overlapped with that seen in CCPRCT. This finding underscores the limited specificity of GPNMB as a diagnostic marker.

  • Measuring Diagnostic Accuracy and Precision of Core Needle Biopsies of Fibroepithelial Breast Lesions to Inform Surgical Management

    by Taylor Salisbury, Karolina Oscilowicz, Nickolas Myles, Carolyn J. Shiau, Ghazal Sokhanran, Anita Zamanigohar, Paria Sokhanran, Lawand Barzinjy, Khashayar Saybani, Neha Khaitan, et al.

    Aims: Fibroepithelial lesions (FELs) of the breast are a heterogeneous group of neoplasms that present diagnostic challenges, particularly on core needle biopsy. This study aimed to evaluate the diagnostic accuracy of breast core biopsy in detecting phyllodes tumors (PTs) using traditional and evidence-based methods, and to identify additional clinical factors that may aid surgical decision-making. Methods and Results: Consecutive core biopsy specimens from 2017 to 2019 were reviewed, with surgical pathology or clinical follow-up as reference standards. Discordant lesions underwent re-review. Diagnostic accuracy was assessed using Bayesian methods, calculating likelihood ratios (LRs) and integrating them with Fagan nomograms to estimate post-test probabilities. Logistic regression identified factors that improved diagnostic precision. Among 425 patients with FELs on biopsy (369 fibroadenoma [FA], 9 PT, 47 indeterminate), 91 underwent excision and 337 had follow-up (mean 36 months). The overall upgrade rate to PT was 19.7%, but only 7% of FA patients upgraded, reflecting a low false-negative rate. Of nine biopsy-diagnosed PTs, seven were confirmed (false-positive rate 22%). Diagnostic LRs demonstrated strong performance: FA (LR = 0.06) effectively ruled out PT, indeterminate FELs (LR = 6) warranted excision, and PT (LR = 78) strongly supported surgical management. Older age and larger tumor size were significantly associated with PT, while BIRADS, needle gauge, clinical presentation, and prior breast cancer were not predictive. Conclusions: Core biopsy effectively stratifies FELs and guides management. While indeterminate lesions remain challenging, integrating clinical factors such as age and size enhances decision-making, reduces overtreatment of FA, and ensures timely diagnosis of PT.


  • In reply to: ‘Prostate cancer with favorable histology is not synonymous with prostate cancer indolence’

    by Jesse K McKenney, James D Brooks, Jane K Nguyen, C K Cornelia Ding, Lisa F Newcomb, Jonathan L Myles, Reza Alaghehbandan, Christopher G Przybycin, Emily Chan, Jeffry P Simko, et al.


  • Open Access

    Classification of prostatic adenocarcinoma as favourable/unfavourable histology has high interobserver agreement in prostate needle core biopsies

    by Chien‐Kuang C Ding, Huijun Xiao, Jane K Nguyen, Christopher G Przybycin, Reza Alaghehbandan, Jonathan L Myles, Nancy Y Greenland, Jeffry P Simko, Deepika Sirohi, Bradley A Stohr, et al.

    Aims: A dichotomous classifier for prostatic adenocarcinoma, favourable and unfavourable histology, was recently proposed to optimize metastasis prediction. We evaluate interobserver agreement for its classification.Methods and results: Fifty biopsies with prostatic adenocarcinoma were selected. One slide per biopsy was scanned using the Aperio AT2 scanner (20x) and viewed in Leica Web Viewer. Ten pathologists reviewed each slide after completing a training module. Biopsies were scored for Grade Group (1–5) and presence of unfavourable histology. Forty‐one of 50 biopsies (82%) had unanimous consensus [13 (32%) unfavourable and 28 (68%) favourable], 47 (94%) for at least 9 of 10 reviewers, and 48 (96%) for at least 8 of 10 reviewers. Percent agreement for favourable/unfavourable classification was 94%, kappa = 0.88 (95% CI: 0.8, 0.96), and Gwet's AC1 coefficient = 0.90 (95% CI: 0.82, 0.97) [both P‐value < 0.001]. Inter‐rater agreement for Grade Group designation was evaluated in biopsies with 100% consensus. In the favourable consensus group (n = 28), kappa for Grade Group was 0.80 (95% CI: 0.62, 0.98) and Kendall's W was 0.83 (95% CI: 0.81, 0.89), with both P‐value < 0.001. For the unfavourable consensus group (n = 13), kappa for Grade Group was 0.56 (95% CI: 0.36, 0.75) and Kendall's W was 0.78 (95% CI: 0.76, 0.85), with both P‐value < 0.001.Conclusions: The classification of prostatic adenocarcinoma as favourable/unfavourable histology has high interobserver agreement, even when learnt through a simple tutorial. GG designation was more variable. This provides evidence that the favourable/unfavourable classification could be utilized in routine practice given its ease of use.


  • Open Access

    Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists

    by Mahra Nourbakshs, Liping Du, Andres M Acosta, Reza Alaghehbandan, Ali Amin, Mahul B Amin, Manju Aron, Daniel Berney, Fadi Brimo, Emily Chan, et al.

    Aims: Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi‐institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.Methods and Results: A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A 5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.Conclusions: Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.


  • Chromophobe Renal Cell Carcinoma With Extensive Retraction Artifact: A Potential Diagnostic Pitfall From Micropapillary Urothelial Carcinoma

    by Ankur R. Sangoi, Kristyna Pivovarcikova, Mahmut Akgul, Sean R. Williamson, Monica Ulamec, Joanna Dominica Rogala, Petr Martinek, Tomas Vanecek, Ondrej Hes, Reza Alaghehbandan

    In addition to “classic” and eosinophilic subtype, chromophobe renal cell carcinoma (RCC) is well-known to demonstrate various morphological patterns including adenomatoid, microcystic, pigmented, multicystic, papillary, neuroendocrine-like, and small cell-like, all of which are important to appreciate for accurate diagnosis. Herein, we expand on a unique chromophobe RCC morphology not previously described consisting of tumor cells with extensive stromal retraction, mimicking upper urothelial tract micropapillary carcinoma (MPC). Twelve MPC-like chromophobe RCC nephrectomies were reviewed with clinicopathological features recorded; molecular testing was performed on 7 of 12 tumors. Patients were mostly men (n=10) with a mean age of 65 years. Mean tumor size was 6.4 cm with pathological stage distribution as follows: 4 (33%) T1a, 2 (17%) T1b, 1 (8%) T2b, and 3 (25%) T3a. The extent of MPC-like chromophobe RCC foci ranged from 10% to 40% (mean=26%; there was no correlation between the extent of MPC-like chromophobe RCC foci and tumor stage). Other chromophobe RCC morphological patterns were not identified. When performed, all (100%) tumors depicted prototypic chromophobe RCC staining pattern of KIT positivity/KRT7 positivity. Molecular showed 6 of 7 (86%) with multiple chromosomal losses. Clinically significant mutations were identified in NF1, TP53, FLCN (likely somatic), CHEK2, and ZFHX3 genes. Follow up available in 9 patients showed no evidence of disease (mean=23 months). Although the etiology behind the extensive stromal retraction in our tumors is unknown, this may likely be artifactual in nature. Nonetheless, it is important to include MPC-like chromophobe RCC in the spectrum of “variant” morphologies to avoid diagnostic pitfalls from micropapillary carcinoma.


  • Open Access

    Anastomosing haemangioma of the adrenal gland: A clinicopathological series of seven cases

    by Reza Alaghehbandan, Erick M Remer, Eren Berber, Jesse K McKenney

    Aims: Anastomosing haemangioma is a rare benign vascular neoplasm that may histologically mimic angiosarcoma. We report the largest single institution series of anastomosing haemangioma in the adrenal gland with emphasis on clinical and radiological features.Methods and results: Our laboratory information system was searched for a 25‐year period (1999–2023), yielding seven cases confirmed as anastomosing haemangioma of the adrenal gland after pathological re‐review. Clinical, radiological and pathological information was obtained from medical charts and submitting pathologists. Of a total of seven patients, four (57.1%) were men and three women, ranging in age from 37 to 75 years (mean = 61). Six of seven patients underwent adrenalectomies and one had radical nephrectomy. Tumours ranged from 0.7 to 6.4 cm (mean = 2.1 cm) and five of seven (71%) were grossly well‐circumscribed. Five of seven lesions were found incidentally at imaging for other indications. All tumours were unifocal except one, which presented with multifocal disease with a concurrent adjacent retroperitoneal anastomosing haemangioma. Three of five tumours imaged with contrast enhancement were almost completely hyperenhancing with a small central non‐enhancing portion, features overlapping with pheochromocytoma. One of seven tumours involved the peri‐adrenal adipose tissue with a focally infiltrative pattern. There were no recurrences or metastases in six patients with available follow‐up data (median = 95 months).Conclusions: Benign anastomosing haemangiomas of the adrenal gland tend to occur in older patients, may mimic pheochromocytoma on imaging and must be distinguished from angiosarcoma pathologically. Better awareness of this entity by pathologists, radiologists and surgeons is crucial to appropriate work‐up, diagnosis and management.